Observations on patents and other IP from a dual-licensed practitioner
Excellent piece in this month's Commentary on the assault on the pharmaceutical industry. And it doesn't even mention patents! Two good quotes: "…it is possible that the average consumer of…
That title is a bit misleading, because Paxlovid does have patent protection. But that wasn't the case when it was first approved. “Paxlovid” is the name given to Pfizer’s product…
James Meigs has a piece in the newest edition of Commentary entitled "Thank God For Big Pharma". It doesn't say anything that's not already familiar to people involved in the…
This is longish post, prompted by a comment made by Dennis Crouch at his PatentlyO blog. Since much of it deals with the background of the Hatch-Waxman amendment, with which…
A friend shared this link to a comic-style presentation of the difficulties inherent in modeling a pandemic. In nutshell, lots of potential variables (not all of which are necessarily relevant…
After last week's fanfare (in Israel, anyway) about the Israeli government exercising rights under section 104 of the patent statute to allow importation of a generic of Abbvie's Kaletra tablets,…
As I mentioned yesterday, the Minister of Health signed an order this week allowing the state to import generic Kaletra (a combination of lopinavir and ritonavir) to be used, potentially,…
This is a story about how a good idea that originated in the Israel PTO tripped over its own shoelaces (in a manner of speaking) when it was eventually enacted…
The hottest story in Israeli biotech in 2017 was the August acquisition of Kite Pharma by Gilead Sciences for 11.9 billion dollars, and the announcement in October of FDA approval…
Interesting news item from last week: according to Allergan’s web site, on September 8 Allergan and the Saint Regis Mohawk Tribe announced that Allergan had assigned several patents to the…
I’m Dan Feigelson. I’ve been practicing patent law for over 30 years. I’m also opinionated, as you may discover in reading my writings here.